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PROTOCOL: A STUDY OF SUSPECTED SCABIES OUTBREAKS IN 
RESIDENTIAL CARE FACILITIES 
 
A suspected scabies case/outbreak is reported to PHE  
 
Public Health England (PHE) are contacted by a primary care physician (GP) or a member 
of staff of a residential care home who suspects it may have a single case or an outbreak of 
scabies. 
 
Action: Day 1  
PHE Health Protection Practitioner (HPP)  
 
1. HPP records the details of the suspected case/outbreak on PHE database (HPZone) 
including the name and contact details (including email addresses) of the person 
reporting the case/outbreak, contact details of the residential care home manager 
and designated residential care home GP (if role exists) and information about the 
residential care home and the number of people affected (including members of 
staff). 
 
2. HPP informs the residential care home manager about the scabies research study 
from a prepared script, explaining that it is an anonymised voluntary study of 
suspected scabies case/outbreaks in homes, that they do not have to participate in 
the study and that if they choose not to participate this will not affect PHE’s 
response to the possible case/outbreak.  
 
3. HPP advises the residential care home manager to expect a call from the research 
team at Brighton and Sussex Medical School (BSMS) with more details about the 
study and to arrange visits.  
 
4. HPP contacts BSMS research team by email or by dedicated study mobile to advise 
that a suspected case/outbreak has occurred, providing all relevant information, 
including summary of correspondence to date.  
 
BSMS Research Coordinator  
 
1. RC contacts Clinician to establish available dates for clinical visit  
 
2. RC contacts the residential care home manager to explain the study in more detail 
and answers any questions raised. RC emails protocol, information sheets, and 
consent forms to the residential care home manager and residential care home GP 
(if role exists). 
 
3. RC organises a convenient date to undertake the preliminary visit and the clinical 
visit to the residential care home. A preliminary visit is still arranged if clinical 
visit cannot be organised before mass treatment has taken place in order that 
outbreak data can be collected.  
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4. RC asks the residential care home manager to arrange for a dedicated staff member 
to be available to assist during the visits as a chaperone.  
 
5. If the care home manager wishes to contact relatives about the study, contact details 
of the research team’s dedicated phone number will be provided and relatives 
encouraged to contact the research team with any questions or queries.  
 
Preliminary visit to the residential care home 
 
Action: Day 2/3  
BSMS Research Coordinator and Project Assistant  
 
1. On arrival the RC introduces herself to the residential care home manager and the 
dedicated staff member and checks that they both understand all aspects of study 
and deals with any questions or queries raised. 
 
2. RC records information about the residential care home and details of the suspected 
outbreak, including suspected cases.   
 
3. With the dedicated staff member acting as chaperone, the RC and PA will establish 
the capacity of all potential participants using the structured MCA guidance form. 
Participants will be given an information sheet (which can be read to them) the 
study will be explained to them in detail and any questions will be answered. 
Residents can choose to take more time to consider whether they want to take part, 
and will be able to confirm their consent during the clinical visit. 
 
4. In the case of an individual who does not have the capacity to consent, the dedicated 
staff member will provide details of suitable contacts who could act as their 
personal consultee.  
 
Following on from the preliminary visit  
 
5. In cases where an individual is unable to give consent, the suggested suitable 
contact will be approached by the RC/ PA. The study will be explained over the 
telephone with any questions answered before their agreement obtained verbally 
and recorded by the RC/ PA. A study information leaflet and a personal consultee 
form will be sent by post for them to sign and return.  If they wish, personal 
consultees can be given time to consider their options and a follow up call can be 
arranged to confirm consent before the clinical visit takes place. 
 
6. If a personal consultee cannot be identified for an individual who does not have 
capacity to consent, we will ask a nominated consultee to consider whether the 
resident should take part in the study. The nominated consultee will be a member 
of care home staff or a GP who is involved in the resident’s care. 
 
 
Version 6Scabies Protocol_23May2014 
3 
 
Clinical Visit  
 
Action: Day 3-5  
Research team: Clinician/BSMS Research Coordinator  
 
RC to introduce the research team to the residential care home manager and the dedicated 
staff member and explain what the visit will involve. The following priority criteria for 
examinations will be used for examinations.  
 
1 Symptomatic residents (where an individual or carer describes signs or 
symptoms suggestive of scabies) 
2 Residents and staff in contact with symptomatic residents in the preceding 4-6 
weeks 
a. In a small care home (less than 40 residents):  
i. All residents and symptomatic staff will be examined 
b. In a large care home (more than 40 residents) 
i. Where the outbreak is confined to the same floor or wing: All 
residents and symptomatic staff will be examined  
ii. Where the outbreak is not confined to the same floor or wing: As 
many symptomatic residents and symptomatic staff will be 
examined as possible given time constraints. 
 
Re-establishing consent  
 
To allow for the possibility of fluctuating capacity, consent for all residents will be re-
established and confirmedbefore any examinations take place.  
 
1. All individuals who had already consented or who had chosen to take time to 
consider taking part in the study will be asked to confirm their consent. If at this 
point any individual does not have capacity to consent, the research team will 
attempt to contact a personal consultee about their participation in the study. If no 
personal consultee can be identified, we will approach a nominated consultee (a 
member of the care home staff or a GP involved in their care) to consider whether 
the individual should take part in the study. 
 
2. Individuals who did not have capacity at the preliminary visit but who now have 
capacity to consent will be provided with an information sheet (which can be read 
to them), and have the study explained to them with any questions answered, before 
being asked if they would like to take part and consent to the study. 
 
3. Individuals who remain without capacity and whose personal or nominated 
consultee has agreed for them to take part will be included in the study.  
  
Once consent has been confirmed  
Residents will be examined in a private setting with a chaperone in attendance for all 
individuals. 
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Individuals are examined by the Clinician: 
 
1. Anonymised personal details and clinical findings will be recorded on the data 
collection form.  
 
2. Skin scrapings will be taken from individuals with lesions suggestive of scabies 
and collected with study number and date of birth.  
 
3. A burrow ink test will be performed on individuals with lesions suggestive of 
scabies and results recorded on the data collection form. 
 
4. Blood samples will be taken from individuals with a scabies diagnosis who 
specifically consent verbally or following personal/nominated consultee advice. 
Samples will be labelled with study number and date of birth.  
5. Digital photographs will only be taken of skin lesions of patients who have 
consented verbally or following whose personal/nominated consultee advice.  
 
6. Images in which individuals would be identifiable (due to facial features or unusual 
scar/tissue or skin lesion) will not be taken for patients who were enrolled in the 
study following personal/nominated consultee advice..  
 
7. Information about health care and contact details of GPs will be recorded for each 
individual.  
 
At the end of the visit  
 
1. The Clinician will complete a summary clinical report about the outbreak as a 
whole in triplicate which should include the number of people examined and the 
diagnoses made at the end of the visit. One copy will be left for the Care Home 
Manager, one sent to the HPP and one retained by the study team. Identifying data 
will be anonymised.  
 
2. The Clinician will complete a standard letter in triplicate to be sent to residents’ 
GPs where symptoms of scabies and/or other conditions which require treatment 
are found. The letter will detail any important coincidental findings, particularly 
suspected skin neoplasia, and advice concerning management. The letter will 
include the contact details of the RC should the GP have any queries. The RC will 
coordinate communication between the GP and the Clinician. One copy will be left 
with the Care Home Manager, one sent to the GP and one copy retained by the 
study team with identifying data anonymised. 
 
3. The Clinician will also complete a standard letter in triplicate for staff where where 
symptoms of scabies and/or other conditions which require treatment are found. All 
findings will be communicated directly to the staff member and a copy given to 
them. One copy will be retained by the study team with identifying data 
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anonymised. Staff may choose whether a copy is sent to their GP, if not this third 
copy will be destroyed    
 
Following on from the clinical visit  
 
Research team: Clinician/ BSMS Research Coordinator  
 
1. An email of thanks will be sent to the residential care home manager and the dedicated 
staff member.  
 
2. Data collected will be entered into secure anonymised database at BSMS. Digital 
photographs will be anonymised and stored on password protected computer and erased 
from the camera.  
 
3. Microscopy of some of the skin flakes will be performed by the microbiology and 
infection service at Brighton and Sussex University Hospital (BSUH) and samples will 
be discarded.  
 
4. Where permission is in place, blood samples and skin flakes will be stored indefinitely 
at Brighton and Sussex Medical School (BSMS) under the BSMS Human Tissue 
Authority Research Licence no: 12561.  Samples will labelled with a sample code and 
recorded on a sample sheet with study identifier. The sample record sheet and a key 
which links the study identifier will be stored separately.  
 
5. Individual letters will be emailed or posted to respective GPs by close of business the 
next working day (i.e. within 72 working hours of visit) 
 
Follow up Clinical Visit  
 
1. A follow up visit will be arranged by BSMS RC to be undertaken approximately 42 
days after the initial clinical visit to re-examine all residents. The same process to re-
establish consent, undertake clinical investigations, store data and communicate 
results will take place as per the previous clinical visit. 
 
2. The care home manager will be asked to complete a questionnaire to feedback the 
experience of taking part in the research study. 
 
Completion of the study  
 
1. The corresponding author of the publication will disseminate to the research group, 
including PHE.  
 
2. BSMS RC will disseminate a copy of a final publication to the participating homes, 
personal consultees and the GPs of all participants involved. A lay summary of the 
research will also be prepared   
